The results of animal studies with ciprofibrate, a new orally effective hypolipidemic drug.

Findings are given to show that ciprofibrate, a new orally active phenoxyisobutyrate, is significantly more hypolipidemic than is the reference clofibrate. In hyperlipidemic rats ciprofibrate suppresses the increase in blood lipids 33% at a daily dosage of 0.6--3 mg/kg.

Relative lipolytic activities of selected catecholamines in the mouse.

The adipokinetic activities, relative to isoproterenol as 1,000, in sedated, phenoxybenzamine pretreated unfasted mice were: norepinephrine 540, epinephrine 330, N-t-butylnorepinephrine 130, isoetharine 30 and N-cyclopentylbutanefrine 10. These relative activities correlate (r=0.88) with the medians of some previously defined beta1-adrenoceptor activities, but not (r=less than 0.